-
公开(公告)号：AU2013226076A2
公开(公告)日：2014-09-25
申请号：AU2013226076
申请日：2013-02-27
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , CAESAR JR JOHN P , FAWAZ MAJED , DAS LAURA , GU CHONG-HUI , HURTER PATRICIA NELL , ISRANI MEGHNA JAI , JOHNSTON MEGHAN M , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , WANG HONGREN
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
-
公开(公告)号：AU2019250116A1
公开(公告)日：2019-10-31
申请号：AU2019250116
申请日：2019-10-15
Applicant: VERTEX PHARMA
Inventor： PHENIX BRIAN DEAN , BAGNOL LAURENT JEAN-CLAUDE , BRODEUR GEOFFREY GLEN , CHANDRAN SACHIN , DOKOU ELENI , FERRIS LORI ANN , MCCARTY KATIE LYNN , MEDEK ALES , KNEZIC DRAGUTIN , WAGGENER SARA A
IPC: C07D215/00 , A61K9/14 , A61K9/16 , A61K9/20 , A61K31/404 , A61K31/47 , A61K45/06 , C07D209/04
Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
-
公开(公告)号：HUE039062T2
公开(公告)日：2018-12-28
申请号：HUE15721912
申请日：2015-04-14
Applicant: VERTEX PHARMA
-
公开(公告)号：RS57476B1
公开(公告)日：2018-10-31
申请号：RSP20180880
申请日：2015-04-14
Applicant: VERTEX PHARMA
Inventor： PHENIX BRIAN DEAN , BAGNOL LAURENT JEAN-CLAUDE , BRODEUR GEOFFREY GLEN , CHANDRAN SACHIN , DOKOU ELENI , FERRIS LORI ANN , KNEZIC DRAGUTIN , MCCARTY KATIE LYNN , MEDEK ALES , WAGGENER SARA A
IPC: A61K45/06 , A61K9/14 , A61K9/16 , A61K9/20 , A61K31/404 , A61K31/47 , C07D209/04 , C07D215/00
-
公开(公告)号：AU2013226076B2
公开(公告)日：2017-11-16
申请号：AU2013226076
申请日：2013-02-27
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , CAESAR JR JOHN P , FAWAZ MAJED , DAS LAURA , GU CHONG-HUI , HURTER PATRICIA NELL , ISRANI MEGHNA JAI , JOHNSTON MEGHAN M , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , WANG HONGREN
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
-
Patent Agency Ranking
公开(公告)号：BR112016023422A2
公开(公告)日：2017-08-15
申请号：BR112016023422
申请日：2015-04-14
Applicant: VERTEX PHARMA
-
公开(公告)号：NZ607494A
公开(公告)日：2015-04-24
申请号：NZ60749411
申请日：2011-08-26
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , ISRANI MEGHNA JAI , DAS LAURA
Abstract: Provided are pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (ivacaftor). In one embodiment a pharmaceutical composition comprises a solid dispersion of amorphous or substantially amorphous ivacaftor in an amount of about 15 to about 47 percent by weight of the composition; sucralose in an amount of about 2 percent by weight of the composition; croscarmellose sodium in an amount from about 3 to about 6 percent of by weight of the composition; sodium lauryl sulfate (SLS) in an amount of about 0 to about 0.5 percent by weight of the composition; colloidal silicon dioxide in an amount of about 1 percent by weight of the composition; magnesium stearate in an amount of about 1.5 percent by weight of the composition; and mannitol in an amount of about 42 to about 77.5 percent of by weight of the composition. The pharmaceutical compositions are useful in the treatment of CFTR mediated diseases, such as cystic fibrosis.
-
公开(公告)号：ZA201301419B
公开(公告)日：2014-07-30
申请号：ZA201301419
申请日：2013-02-25
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , DAS LAURA , ISRANI MEGHNA JAI , KNEZIC DRAGUTIN , KUZMISSION ANDREW G
IPC: A61K20060101
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition.
-
公开(公告)号：MX2013002353A
公开(公告)日：2013-09-26
申请号：MX2013002353
申请日：2011-08-26
Applicant: VERTEX PHARMA
Inventor： KNEZIC DRAGUTIN , ELENI DOKOU , SHAHLA JAMZAD , DAS LAURA , ISRANI MEGHNA JAI , KUZMISSION ANDREW G
Abstract: La presente invención se relaciona con composiciones farmacéuticas que contienen una dispersión de sólidos de N-[2,4-Bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquin olin-3-caboxamida incluyendo las formulaciones de las dispersiones de sólidos en polvos, gránulos y mini-tabletas, los métodos para la elaboración y procesamiento de los polvos y mini-tabletas y los métodos para tratar la fibrosis quística empleando la composición farmacéutica.
-
公开(公告)号：MX2011002312A
公开(公告)日：2011-04-26
申请号：MX2011002312
申请日：2009-08-28
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , GASPARAC REHELA , KNEZIC DRAGUTIN
Abstract: Una formulación de liberación inmediata de un ingrediente activo, en donde el ingrediente activo es un co-cristal de VX-950 y un acido 4-hidroxibenzoico.
-
-
-
-
-
-
-
-
-
Search Results
55
records
(took 0.022 seconds)
